Cipla to set up Rs.1.3-bn biotech plant in SA
The Dollar Business Bureau Cipla BioTec, the research and development subsidiary of Cipla, will invest around Rs.1.3 billion to set up state-of-the-art manufacturing plant for the production of biosimilars in South Africa. The global pharmaceutical firm owns the third largest pharma company in South Africa - Cipla Medpro. Subhanu Saxena, MD and Global CEO of Cipla Ltd said that the investment will facilitate to create the first bio-cluster in Africa. A state-of-the-art manufacturing base in South Africa will provide new opportunities for the partners in supply chain. This will further allow high level research efforts to sustain in South Africa. The biotech manufacturing unit will attract research from global institutions. This facility will have all the required design capabilities. It will seek regulatory approvals ...
Govt clears 10 FDI proposals worth Rs. 607 crore
The approved proposals included those sought by Alstom Manufacturing India Limited and pharma majors like Cipla, Glenmark, Emcure, and Celestis The Dollar Business Bureau In the pharma sector, Cipla has got the go-ahead to bring in a maximum Rs. 145.22 crore from Mauritius-based FIL Capital Investments Limited The government has cleared 10 foreign direct investment (FDI) proposals, allowing an inflow of up to Rs.607 crores mainly in pharmaceuticals and railway infrastructure sectors in the country. The approved proposals included those sought by Alstom Manufacturing India Limited and pharma majors like Cipla, Glenmark, Emcure, and Celestis. Based on the recommendations of Foreign Investment Promotion Board in its 231st meeting held on 22nd January 2016, the government has approved 10 FDI proposals involving FDI of Rs. ...
